Peptide functionalized liposomes for receptor

Purpose: Most clinically approved cancer therapies are potent and toxic small molecules limited by severe off-target toxicities and poor tumor-specific localization. Liposomal encapsulation reduces toxicity, but reliance on passive targeting via the enhanced permeability and retention (EPR) effect leaves unresolved issues such as heterogeneous tumor accumulation. Peptide-functionalized liposomes offer an active targeting strategy for receptor-mediated tumor homing and controlled chemotherapeutic delivery.

Hypothesis: As a review, there is no single experimental hypothesis. Central thesis: if liposomes are surface-functionalized with peptides that bind receptors overexpressed on tumor cells or tumor vasculature, then receptor-targeted delivery can improve tumor localization, cellular uptake, and therapeutic efficacy while reducing off-target effects. D-enantiomeric peptides, multimeric ligands, and novel receptor-specific sequences may further enhance stability, binding affinity, and clinical potential.

Aims: Provide a comprehensive summary of peptide-functionalized liposomes for receptor-targeted cancer therapy over the past five years. - Describe peptide ligands targeting tumor and tumor microenvironment receptors, including TfR, EGFR/HER2, APN, VEGFR2, integrins, GRPR, IL-13Rα2, and gp130. - Compare conjugation strategies, peptide sequences, binding affinities, and in vitro/in vivo outcomes. - Discuss future directions, limitations, and clinical translation challenges.

Delivery system: Platform: Liposomes, including small unilamellar vesicles (SUVs <100 nm), medium unilamellar vesicles (MUVs 100–250 nm), large unilamellar vesicles (LUVs >250 nm), and giant unilamellar vesicles (GUVs). - Payloads: Chemotherapeutics—doxorubicin, docetaxel, quercetin, paclitaxel, gemcitabine, shikonin, combretastatin A4, clengitide, sodium borocaptate, cytarabine, daunorubicin, irinotecan, vincristine, mifamurtide; nucleic acids—siRNA (e.g., ABCG2 siRNA). - Targeting peptides: T7 (HAIYPRH) for TfR; GE11 (YHWYGYTPQNVI) for EGFR/HER1; P6.1 (KCCYSL), HER-2 peptide, AHNP for HER2; NGR, LN (YEVGHRC) for APN; STP, TP, S1, A7R, D7, cyclic A7R for VEGFR2; linear RGD, cyclic RGD variants, RWrNK, P1c for integrins; cystabin for GRPR; Pep-1 for IL-13Rα2; VTW for gp130. - Conjugation methods: Covalent conjugation via amide bonds (activated carboxyl + amino), disulfide bonds (pyridyldithiol + thiol), thioether bonds (maleimide + thiol), carbamate bonds (p-nitrophenylcarbonyl + amino); or electrostatic/hydrophobic adsorption/intercalation. PEG linkers are commonly used, though alternative linkers such as (VPGVG)\(_n\) and (SO\(_n\)) have been explored.

Approach: Review of in vitro and in vivo studies from the past five years. No new experimental data. In vitro cell lines include HepG2, A549, MRC-5, MDA-MB-231, BT-474, MCF-7, SKBR3, TUBO, U87-MG, HUVECs, 293T, HT-29, U251MG, and others. In vivo models include HepG2 xenografts, A549 lung cancer, TUBO breast cancer, U87 glioma orthotopic models, and HT-29 colon adenocarcinoma xenografts in mice. Clinical trials of peptide-functionalized liposomes are mentioned as progressing but not detailed. Not a systematic review.

Key methods: Surface plasmon resonance (SPR) for binding affinity (K\(_D\)); in vitro cytotoxicity (IC\(_{50}\)); cellular binding/uptake assays; in vivo tumor accumulation using fluorescent/DiD-labeled liposomes; tumor growth inhibition; survival curves (Kaplan-Meier); immunohistochemistry (Ki67); transmission electron microscopy (TEM); confocal microscopy; ex vivo organ imaging; phage display and microarray for peptide discovery; future use of machine learning proposed.

Key results: TfR-targeting T7: D-enantiomer T7 showed increased binding affinity over L-T7 and transferrin; T7-liposomes loaded with docetaxel significantly reduced tumor growth in mice. T7-quercetin liposomes increased cytotoxicity 3-fold versus free drug and improved tumor penetration depth. - EGFR-targeting GE11: Dox-loaded GE11 liposomes reduced IC\(_{50}\) 2.6-fold versus nontargeted control and showed 2.2-fold greater tumor fluorescence. GE11 liposomes co-delivering docetaxel and ABCG2 siRNA enhanced tumor growth inhibition in Hep-2 xenografts. - HER2-targeting P6.1: Tetrameric P6.1 liposomes showed 10-fold greater binding/uptake in HER2-overexpressing BT-474 vs MDA-MB-231 cells, comparable to Herceptin. - VEGFR2-targeting A7R: K\(_D\) = 6.79 nM; >80% and 90% targeting/internalization in HUVEC and U87 cells, respectively; improved survival in U87 xenografts. - Integrin-targeting c(RGDfK)/Pep-22 co-modified Dox liposomes: Improved survival (36.5 days vs 26.5 days for pHA+c(RGDyK)), decreased liver accumulation, and increased tumor localization in glioma-bearing mice. - IL-13Rα2-targeting Pep-1: Cellular uptake improved from 47.5% to 89.8%; significant reduction in tumor volume in U87 xenograft mice.

Interpretation: Peptide-functionalized liposomes have demonstrated promising tumor targeting, increased cellular uptake, improved tumoral localization, and efficient drug delivery across many cancer models. D-enantiomers can increase serum stability and binding, and multimeric peptides can enhance affinity. Although only unmodified or PEGylated liposomal therapeutics are clinically approved, numerous clinical trials of peptide-functionalized liposomes are progressing. Future advances should include structure-function studies, novel sequence discovery via phage display/microarray/machine learning, synergistic combination therapies, and exploration of D-enantiomers and chirality effects.

Limitations: This is a review, not a primary study. Only unmodified or PEGylated liposomal therapeutics are clinically approved; peptide-functionalized liposomes remain in clinical trials. Limitations include systemic clearance by immune cells, multidrug resistance, protease degradation, serum protein binding to conjugated peptides, costly and laborious empirical screening, and potential off-target delivery. PEG immunogenicity is a concern. No large-animal validation or long-term safety data are presented.